TREAT PTSD VA Act
- Sponsor
- Rep. Perry, Scott [R-PA-10]
- Committees
- Veterans' Affairs Committee (primary)
- Last action
- May 12, 2026
Bottom line
This bill mandates the Department of Veterans Affairs to offer stellate ganglion block therapy for veterans with PTSD and update clinical guidelines to reflect its availability.
What it actually does
This bill directs the Department of Veterans Affairs (VA) to furnish stellate ganglion block (SGB) to any veteran enrolled in the VA patient system who has been diagnosed with post-traumatic stress disorder (PTSD) and elects to receive the treatment. It also mandates that the VA update its joint clinical practice guideline for PTSD to include information on SGB as a therapy option.
Proponents argue
Supporters argue that stellate ganglion block is a promising, minimally invasive treatment for PTSD symptoms, offering rapid relief to veterans who may not respond to traditional therapies. Mandating its provision ensures access and reduces barriers to care for a critical population, empowering veterans with choice and ensuring the VA keeps pace with emerging medical options.
Opponents contend
Critics might raise concerns about the evidence base for SGB as a mandated treatment, potential costs, and whether mandating specific treatments interferes with clinical autonomy or resource allocation for other proven therapies. They may also question if legislative mandates are the most appropriate mechanism for integrating new medical procedures.
The bill is very short and clearly written, making it easy for an informed reader to understand its core provisions quickly.
Section 2(a), amending Subchapter II of chapter 17 of title 38, United States Code, by adding new section 1720M.
Mandated Provision of Stellate Ganglion Block for Veterans with PTSD
This provision requires the Department of Veterans Affairs (VA) to furnish stellate ganglion block (SGB) to any veteran who is enrolled in the VA patient system, has been diagnosed with post-traumatic stress disorder (PTSD), and chooses to receive the treatment after being informed of its risks and benefits by a qualified healthcare provider. The VA is authorized to provide this care either through its own medical facilities or through external healthcare providers.
Supporters argue
Supporters argue this provision directly addresses a critical need for alternative PTSD treatments, providing veterans with a potentially life-changing therapy that may offer rapid symptom relief where other treatments have failed. It empowers veterans with choice and ensures the VA keeps pace with emerging medical options.
Critics contend
Opponents might contend that mandating a specific medical procedure, even a promising one, could set a problematic precedent, potentially diverting resources from other evidence-based treatments or limiting the VA's flexibility in clinical decision-making based on evolving research and resource availability.
Tradeoffs
The tension lies between ensuring access to a potentially effective treatment for veterans and maintaining clinical autonomy and flexibility within the VA to allocate resources based on the broadest evidence base and evolving medical consensus. It balances patient choice with institutional discretion.
Section 2(b)
Update VA/DOD Clinical Practice Guideline for PTSD
This section directs the Secretary of Veterans Affairs to update the joint VA/DOD Clinical Practice Guideline for the Management of PTSD within 180 days of the bill's enactment. The update must ensure the guideline reflects the availability of stellate ganglion block (SGB) as a therapy option and includes comprehensive information on its clinical indicators (when it's appropriate) and contraindicators (when it's not appropriate). The Secretary is also required to notify the House and Senate Committees on Veterans' Affairs once the guideline has been updated.